腹膜透析患者伴高脂血症的降脂治疗

观察simvastatin治疗腹膜透析伴脂质代谢紊乱患者的疗效及其对残存肾功能的保护作用。 47例伴高脂血症的腹膜透析患者随机分为两组。对照组予持续性不卧床腹膜透析及内科常规降压、护肾治疗 ;治疗组在对照组治疗基础上加服simvastatin。结果示 ,与对照组比较 ,治疗组经降脂治疗 1 2周后其血清总胆固醇、甘油三酯、低密度脂蛋白、载脂蛋白B1 0 0明显降低 ,高密度脂蛋白、载脂蛋白A1明显升高 (P <0 .0 5) ;继续观察一年两组病人的残存肾功能均下降 ,但两组间差异不明显。提示simvastatin能有效纠正腹膜透析患者的脂质代谢紊乱 ,但对残余肾功能的保护作用不明显

Effects on simvastatin in continuous ambulatory peritoneal dialysis patients with hyperlipidemia

The therapeutic effects of simvastatin on hyperlipidemia and its protective effects on residual renal function (RRF) in continuous ambulatory peritoneal dialysis (CAPD) patients with hyperlipidemia were observed. Forty seven CAPD patients were randomly divided into two groups, the treatment group and control group. The treatments of two groups were the same except that the treatment group patients were additionally given simvastatin 20 mg·d -1 . The results were that, after 12 week treatment, the total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL), and apoprotein B100 (ApoB100) in the treatment group significantly decreased, but high density lipoprotein (HDL) and apoprotein A1 (ApoA1) significantly increased compared with the control group (all P<0.05); one year later, RRF of patients of both groups all decreased but there was no significant difference between them. The results suggest that simvastatin can effectively normalize lipidemia, but has no protective effect on RRF in CAPD patients.